Can You Get Allergy Shots for Seasonal Allergies? Eligibility and Strategy

Year-round maintenance injections are required even for purely seasonal allergens because immune tolerance is not self-sustaining without regular antigen exposure. The IgG4 blocking antibodies and regulatory T-cell populations that suppress your allergic response need ongoing allergen exposure to maintain their suppressive activity. If you received injections only during pollen season and stopped during your symptom-free months, these tolerance-inducing immune cells would gradually lose the activation signal they need to remain effective. Research shows that year-round maintenance produces significantly superior long-term tolerance compared to seasonal-only or pre-seasonal-only injection schedules. The good news: maintenance visits are monthly, not weekly — so the year-round commitment after completing build-up is approximately 12 visits per year, not 52.

Starting allergy shots during your peak seasonal allergy period is possible but comes with tradeoffs. The preferred approach is pre-seasonal initiation — starting 3-4 months before your peak season to reach maintenance dose before maximum allergen exposure. Starting during active season may result in higher local reaction rates and some increased discomfort during the already-reactive period. However, for patients who are ready to start and cannot wait, in-season initiation is not a clinical contraindication. Allergists may use a more conservative dose escalation schedule in-season to minimize reaction risk. Cluster immunotherapy protocols can also accelerate build-up to 4-8 weeks even when starting during the season. The important expectation to set: starting during your current allergy season will not provide meaningful symptom relief for that same season — the treatment benefits develop over months and will be most apparent in the following year.

Yes — allergy shots improve allergic conjunctivitis (eye symptoms) as well as nasal symptoms in seasonal allergy patients. The same IgE-mediated immune mechanism drives both nasal rhinitis and ocular symptoms in seasonal allergy. By modifying the underlying immune response to the relevant pollen or seasonal mold allergens, immunotherapy reduces allergic reactivity at all sensitized mucosal surfaces — eyes, nose, and airways simultaneously. Multiple trials of grass pollen immunotherapy have documented improvement in total nasal symptom scores AND ocular symptom scores compared to placebo, with effect sizes comparable for both symptom domains. The ARIA guidelines and EAACI position statements both recognize allergic rhinoconjunctivitis (combined nasal and eye disease) as a primary indication for immunotherapy. Patients with both nasal and eye symptoms should mention both to their allergist — the extract formula addresses the underlying sensitization, benefiting all symptom manifestations.

Most seasonal allergy patients notice partial improvement during their first treated allergy season — typically 3-6 months into the build-up phase if started pre-seasonally. Full benefit develops over 12-18 months of consistent maintenance treatment, with most patients reporting maximum improvement in their second or third treated season. The Cochrane review by Calderon et al. (2007) analyzed 51 randomized controlled trials and found significant symptom reduction averaged across patient-years of treatment. Individual variation is meaningful: some patients see dramatic improvement in their first season; others need a second full treated season before reaching maximum benefit. Setting expectations accurately: if you start allergy shots in October and your spring pollen season peaks in April, you may experience partial but not full protection in April. By the following spring, after one year of maintenance, protection is typically substantially greater.

Yes — one of the most compelling benefits of seasonal allergy immunotherapy is disease modification: the prevention of new allergic sensitizations and the prevention of allergic rhinitis progressing to asthma. Without treatment, seasonal allergies often worsen over time as patients develop new sensitivities to additional allergens — a phenomenon called sensitization expansion. The PAT study (Moller et al., JACI, 2002) demonstrated that children who received immunotherapy for seasonal allergic rhinitis developed significantly fewer new allergen sensitizations and had 50% less asthma development over 10 years compared to pharmacotherapy-only controls. Adult patients also show some evidence of disease modification, though the effects are less dramatic than in children. Antihistamines and nasal steroids, by contrast, only suppress current symptoms and provide no disease-modification benefit — the allergy progression continues regardless.

Seasonal allergy patients need allergy shots year-round — not just during pollen season. This is one of the most common misconceptions about immunotherapy for seasonal triggers. While symptoms are seasonal, the immune tolerance mechanism requires sustained antigen exposure throughout the year to remain effective. Monthly maintenance injections during symptom-free months — fall, winter, or whatever months are outside your peak season — are as important as the peak-season injections. Think of it as continuous immune training rather than seasonal treatment. Stopping during off-season months would cause the tolerance to wane, similar to stopping antibiotics before completing a full course. The year-round requirement applies equally to single-allergen and multi-allergen protocols. Patients who try seasonal-only immunotherapy on their own initiative consistently show inferior outcomes compared to year-round protocols in clinical observations.